NEW YORK: Chemeleon, a disruptive innovator in diagnostic technology, today announced a collaboration with Mayo Clinic to complete development and clinical validation of their ultra-rapid, instrument-free assay poised to redefine point-of-care (POC) testing in emergency settings. This collaboration will focus on clinical optimization of Chemeleon’s flagship high-sensitivity cardiac troponin (hs-cTn) assay and explore the application of their platform technology to other acute care conditions beyond cardiac care. Coinciding with this milestone, the company has launched a $10M Series A funding round to help bring this transformative technology to market.
The ultra-rapid, POC assay leverages Chemeleon’s patented Binding-Induced Nanostructured Dynamic Surface (BINDS™) technology to deliver results in seconds rather than hours, dramatically accelerating clinical-decision making and transforming patient outcomes. Collaborating with Mayo Clinic enables enhanced clinical validation, diagnostic protocol optimization, and a clear path to adoption. “With Mayo Clinic’s deep clinical expertise, we’re accelerating a future where faster diagnosis can mean faster treatment for life-threatening conditions in and out of the emergency department,” said Brendan Walker, CEO of Chemeleon.
The Series A will fund clinical trials, FDA clearance, and initial market entry into a $15 billion acute care diagnostics market.
